• ABT-199 Workflows for Apoptosis Research

  2026-09-23

  Build selective BCL-2 inhibition into apoptosis assays with practical guidance on model choice, dose-response design, and troubleshooting. A senescence-focused reference study adds an important boundary: its findings concern ABT-263, so ABT-199 requires its own target-dependence tests.

• OTUD3, SLC7A11, and Sunitinib Resistance in ccRCC

  2026-09-23

  The reference study identifies OTUD3 as a deubiquitinase that stabilizes SLC7A11, limits ferroptosis, and promotes sunitinib resistance in clear cell renal cell carcinoma. Its mechanistic framework connects protein turnover with cystine metabolism and provides a rationale for testing OTUD3-directed strategies alongside sunitinib.

• BCA Protein Quantification Kit K4102

  2026-09-22

  The Bicinchoninic Acid Assay (BCA) Protein Quantification Kit K4102 supports sensitive total-protein measurement in dilute biochemical samples, cell lysates, and many detergent-containing preparations. It is intended for scientific research and sample normalization, not diagnostic, clinical, or medical testing.

• CUDC-907 Dual PI3K/HDAC Workflow Guide

  2026-09-22

  CUDC-907 (SKU A4097) provides a controlled in vitro approach for examining coordinated PI3K and HDAC pathway modulation, including phosphoprotein changes, histone acetylation, cell-cycle behavior, and apoptosis. This guide is based on the product dossier and workflow practice rather than a directly matched paper, and the compound is intended only for scientific research, not diagnostic, therapeutic, or clinical use.

• HOXC8, Caspase-1, and Pyroptosis in Lung Cancer

  2026-09-21

  A 2025 Cell Death and Disease study identifies HOXC8 as a transcriptional suppressor of caspase-1 in non-small cell lung carcinoma. Its depletion increases CASP1 abundance and triggers ASC-independent, GSDMD-dependent pyroptosis, revealing an epigenetic mechanism that may help explain how HOXC8 supports lung tumorigenesis.

• Repaglinide for Metabolic Stress and DNA Repair

  2026-09-21

  Repaglinide can serve as a reversible metabolic perturbation in experiments probing the energy–DNA repair connection in acute myeloid leukemia. This workflow combines dose and timing controls with ATG4B localization, PRMT1–MRE11 signaling, DNA damage, and viability readouts while clearly separating exploratory use from validated mechanism.

• LY2886721: Tuning BACE1 Inhibition for Translation

  2026-09-20

  LY2886721 offers a mechanistically precise way to investigate BACE1-dependent amyloid precursor protein processing, connect amyloid beta reduction with CSF biomarkers, and define exposure levels that preserve synaptic function. This thought-leadership guide translates its cellular and animal evidence into a practical workflow for Alzheimer’s disease researchers.

• Actinomycin D for RNA Stability in TNBC

  2026-09-19

  Actinomycin D can convert transcriptional inhibition into a rigorous test of mRNA stability in triple-negative breast cancer models. This article connects ActD assay design with RBMS1–B4GALT1–PD-L1 biology while defining controls that prevent transcriptional stress from being mistaken for immune-regulatory mechanism.

• NU7441 (KU-57788) DNA-PK Inhibitor Guide

  2026-09-18

  NU7441, also called KU-57788, is an ATP-competitive DNA-PK inhibitor used in DNA repair research and oncology research. Its reported biochemical selectivity, DMSO solubility, and example cell and xenograft workflows support controlled studies of DNA damage response signaling.

• BEND Lipids Improve mRNA Delivery and Gene Editing

  2026-09-18

  The reference study introduces branched endosomal disruptor (BEND) ionizable lipids as a platform for improving lipid nanoparticle delivery of mRNA and CRISPR-Cas9 ribonucleoproteins. Its complementary delivery, editing, and mechanistic experiments connect terminal lipid branching with enhanced endosomal penetration, hepatic gene editing, and T-cell transfection.

• Iptacopan: From Factor B Mechanism to Translation

  2026-09-17

  A translational framework for using Iptacopan (LNP023) to connect selective factor B inhibition with quantitative complement assays, disease models, clinical biomarkers, and evidence-based development strategy.

• BHQ: From SERCA Biology to HSC Mobilization

  2026-09-17

  A translational perspective on how 2,5-di-tert-butylbenzene-1,4-diol (BHQ) connects SERCA inhibition, calcium homeostasis disruption, ER stress, and hematopoietic stem cell mobilization—while defining the controls needed to move from mechanistic observation to robust research strategy.

• Iptacopan (LNP023) Complement Research Workflows

  2026-09-16

  Build more informative complement experiments with a selective, reversible factor B inhibitor that connects enzyme-level potency to serum C3bBb activity, hemolysis, and disease-model endpoints. This workflow-oriented guide covers assay design, translational use cases, and troubleshooting for Iptacopan (LNP023).

• Polyphyllin H Reverses Paclitaxel Resistance

  2026-09-16

  The reference study identifies membrane cholesterol and lipid rafts as a shared regulatory environment for ABCB1 and ABCC3 in paclitaxel-resistant breast cancer. Its findings suggest that Polyphyllin H can restore paclitaxel accumulation and antitumor activity through multi-transporter, cholesterol-directed resistance reversal rather than single-transporter inhibition.

• DHEA at the Ovarian–Neural Translation Interface

  2026-09-15

  Dehydroepiandrosterone (DHEA) is more than a steroidal reagent: it is a strategically useful perturbation tool for connecting ovarian steroidogenesis, mitochondrial regulation, apoptosis inhibition, and neuroprotection while maintaining clear boundaries between disease modeling and therapeutic interpretation.

8661 records 1/578 page Next 12345 下5页 Last page